EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer

Nikita V Baclig, Madhuri Chengappa, Andrew J Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyne Face, Saliha Chaudhry, Dame Idossa, Thejaswi Poonacha, Laura Huppert, Laura Quintal und 10 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.07.026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Nikita V Baclig und 21 weiteren Autor:innen. Beteiligte Einrichtung: University of California Los Angeles, Department of Medicine, Los Angeles, CA. Electronic address: nbaclig@mednet.ucla.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly used in metastatic breast cancer (mBC), yet real-world data on immune-related adverse events (irAEs) are limited. PATIENTS AND METHODS: We conducted a retrospective cohort study across 4 NCI-designated cancer centers. Adults with mBC treated with ICIs between 2014 and 2024 were included. irAEs were defined by provider attribution or treatment with high-dose corticosteroids and exclusion of other clear causes. Predictors of irAE were assessed using multivariable logistic regression. Overall survival (OS) was evaluated using a 12-week landmark analysis. RESULTS: Among 522 patients (mean age 55.4), most received pembrolizumab (83.9%) and ICI in combination (82.7%). Over a median follow-up of 17.5 months, 42.5% experienced ≥1 irAE and 13.2% had severe (grade 3-4) events. Lower odds of irAE were observed for Black race (OR 0.43; P = .028), low albumin (OR 0.50; P = .007), and low hemoglobin (Hgb) (OR 0.60; P = .009), while higher odds were associated with age 46-55 (OR 1.76, P = .035), CDK4/6 inhibitor use (OR 1.82; P = 0.030) and ≥4 ICI cycles (OR 1.70; P = .007). Among 332 patients included in the landmark analysis, grade 1-3 irAEs were associated with superior OS compared with no irAE, whereas grade 4 irAEs were associated with inferior OS (log-rank P < .0001). CONCLUSION: In this multi-institutional real-world cohort of mBC patients treated with ICIs, irAEs were more frequent than reported in breast cancer clinical trials. ICI duration and CDK4/6 inhibitor use increased irAE risk, while baseline albumin influenced survival. Mild-to-moderate irAEs were associated with improved outcomes, but severe irAEs portended worse survival. These findings support risk-stratified ICI use in mBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsHumansFemaleMiddle AgedRetrospective StudiesRisk FactorsIncidenceAgedAdultSurvival Rate

Stichwörter der Autor:innen

Immune checkpoint inhibitorImmunotherapyPD-1 PD-L1 inhibitorToxicity

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • University of California Los Angeles, Department of Medicine, Los Angeles, CA. Electronic address: nbaclig@mednet.ucla.edu.
  • University of Minnesota, Masonic Cancer Center, Department of Medicine, Minneapolis, MN.
  • University of California Los Angeles, Department of Medicine, Los Angeles, CA.
  • University of Pennsylvania, Department of Medicine, Philadelphia, PA.
  • University of California San Francisco, Department of Medicine, San Francisco, CA.
  • City of Hope Comprehensive Cancer Center, Department of Medicine, Duarte, CA.

Zitieren

APA

Baclig, N. V., Chengappa, M., Soliman, A. J., Jacob, S., LeVee, A., Fisch, S., Face, C., Chaudhry, S., Idossa, D., Poonacha, T., Huppert, L., Quintal, L., Melisko, M., Majure, M., Tsai, K., Kordic, A., Chien, J., Mortimer, J., Rugo, H. S., …, & McCann, K. E. (2026). Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.026

Vancouver

Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, et al. Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.07.026

BibTeX
@article{Baclig2026,
  author = {Baclig, Nikita V and Chengappa, Madhuri and Soliman, Andrew J and Jacob, Saya and LeVee, Alexis and Fisch, Samantha and Face, Carolyne and Chaudhry, Saliha and Idossa, Dame and Poonacha, Thejaswi and Huppert, Laura and Quintal, Laura and Melisko, Michelle and Majure, Melanie and Tsai, Karen and Kordic, Austin and Chien, Jo and Mortimer, Joanne and Rugo, Hope S and Lechner, Melissa G and Blaes, Anne and McCann, Kelly E},
  title = {Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.07.026}
}
Kostenlos starten →